Thermo Fisher Scientific has introduced the Ion Torrent Oncomine Myeloid assay GX v2, a next-generation sequencing (NGS) assay designed to allow researchers to gather comprehensive mutational results from myeloid samples in a day, using the Ion Torrent Genexus System.
As the list of myeloid biomarkers continues to grow, the company says, rapid and streamlined solutions are increasingly valuable for analysis of complex and heterogeneous myeloid malignancy samples. This latest assay offers a panel to profile key biomarkers for all major myeloid disorders with minimal hands-on time, the company claims.
It’s designed to detect a wide range of variants, including challenging-to-sequence targets such as FLT3-ITD, CALR and CEBPA. The updates for this version include additional DNA and RNA targets, improved sequencing of key GC-rich regions, the ability to run the RNA and DNA panels separately, and availability on the company’s Genexus System for improved workflow.
